DailyIQ
|
Sector:HealthcareAll sectors
Last updated 100 days ago

ARGX·ARGX

$.
-. (-.%)
After Hours
High
$851.92
Open
$834.11
Market Cap
43.50B
52W High
$810.00
Low
$817.20
P. Close
$833.54
P/E
33.67
52W Low
$456.60
Fwd P/E
-
Mean Target
-
Technical Score (1D)
32
SELL
News Sentiment
48
MIXED
Today's analysis focuses on recent valuation assessments for ARGX. A recent article from Simply Wall St. examines argenx's valuation, considering recent share price declines. This analysis uses various valuation methods to assess the current share price against the company's potential worth. The stock has shown short-term weakness, but longer-term gains are still in place. In a separate analysis, Zacks compares ARGX to HRMY, assessing them for value. This comparison highlights HRMY's Strong Buy rating versus ARGX's Hold rating, indicating a more favorable earnings outlook for HRMY. The Zacks analysis focuses on earnings estimate revisions as a key factor in their ratings. Investors should watch for further earnings revisions and analyst ratings to gauge the relative value of these biotech stocks.
Earnings Summary
argenx SE is a commercial-stage biotechnology company focused on developing therapies for autoimmune diseases, operating within the healthcare sector. The company's primary focus is on treatments for conditions like generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). Recent quarterly performance shows that in Q4 2024, the company reported revenue of $724,376,950.0, while the EPS actual was 0.71246, missing the estimated EPS of 1.69785. Not enough information is available to compare the last two quarters. The provided data does not allow for a historical streak analysis. Recent news indicates the FDA granted priority review for Vyvgart's supplemental biologics license application, which could expand its use, and analysts maintain positive ratings, citing strong sales momentum. Investors should watch for the impact of the FDA's decision on Vyvgart's expanded use and the continued sales momentum of Vyvgart in the coming quarters.

EPS

EstBeatMiss
$0.56$0.88$1.21$1.53$1.85Q4'24
QtrEstActual+/−
Q4'24$1.70$0.71-58.0%

Revenue

EstBeatMiss
$724M$724M$724M$724M$724MQ4'24
QtrEstActual+/−
Q4'24 - $724M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ARGX Stock Snapshot

ARGX is currently trading at $821.96, giving ARGX a market cap of 43.50B and a P/E ratio of 33.7. Today's range spans $817.20–$851.92, with shares opening at $834.11 and moving down $11.58 (1.4%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 48/100.

Over the past year ARGX has traded between $456.60 and $810.00 - the current price is +80.0% off the 52-week low and +1.5% from the high.

ARGX is showing a SELL signal (32/100) with neutral sentiment (48/100). Price: $821.96 (near 52-week highs within $456.60–$810.00). (P/E: 33.7) At 43.50B in Healthcare market cap, a bearish technical read accompanied by negative sentiment often marks the beginning of an earnings revision cycle downward - active managers trim before the revisions become consensus, compounding the selling pressure.

Analyst coverage for ARGX becomes a double-edged factor in a SELL phase: at 43.50B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 32/100 technical reading and neutral sentiment (48/100) at $821.96 (near 52-week highs) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $456.60–$810.00 range establishes where that repricing lands.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…